Free Trial
NASDAQ:HOTH

Hoth Therapeutics (HOTH) Stock Price, News & Analysis

Hoth Therapeutics logo
$0.86
+0.01 (+1.18%)
(As of 11/1/2024 ET)

About Hoth Therapeutics Stock (NASDAQ:HOTH)

Key Stats

Today's Range
$0.86
$0.91
50-Day Range
$0.69
$1.26
52-Week Range
$0.58
$1.73
Volume
131,039 shs
Average Volume
1.45 million shs
Market Capitalization
$5.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50
Consensus Rating
Buy

Company Overview

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Hoth Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
66th Percentile Overall Score

HOTH MarketRank™: 

Hoth Therapeutics scored higher than 66% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hoth Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Hoth Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Hoth Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Hoth Therapeutics are expected to grow in the coming year, from ($1.18) to ($0.87) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Hoth Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Hoth Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Hoth Therapeutics has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Hoth Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    4.58% of the float of Hoth Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Hoth Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    Hoth Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Hoth Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.58% of the float of Hoth Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Hoth Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • News Sentiment

    Hoth Therapeutics has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Hoth Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for HOTH on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Hoth Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Hoth Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $16,750.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    10.56% of the stock of Hoth Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.08% of the stock of Hoth Therapeutics is held by institutions.

  • Read more about Hoth Therapeutics' insider trading history.
Receive HOTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HOTH Stock News Headlines

Crypto Crash Ahead? (27 Experts Weigh In)
Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!
Hoth Therapeutics, Inc.
See More Headlines

HOTH Stock Analysis - Frequently Asked Questions

Hoth Therapeutics' stock was trading at $1.44 at the start of the year. Since then, HOTH shares have decreased by 40.3% and is now trading at $0.86.
View the best growth stocks for 2024 here
.

Hoth Therapeutics, Inc. (NASDAQ:HOTH) issued its quarterly earnings data on Friday, August, 9th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.15.

Hoth Therapeutics shares reverse split on the morning of Wednesday, October 26th 2022. The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Hoth Therapeutics (HOTH) raised $8 million in an IPO on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hoth Therapeutics investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Meta Platforms (META), NVIDIA (NVDA) and Zomedica (ZOM).

Company Calendar

Last Earnings
8/09/2024
Today
11/02/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HOTH
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.50
High Stock Price Target
$4.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+307.0%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$-7,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.03 per share

Miscellaneous

Free Float
6,175,000
Market Cap
$5.94 million
Optionable
Not Optionable
Beta
0.84
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:HOTH) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners